PCK2 and hepatocellular carcinoma: Given the pivotal role of the IGF2BP3lac‐PCK2 axis in lenvatinib‐resistant patients, we believe that targeting this axis could represent a novel intervention strategy for lenvatinib‐resistant HCC.